Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Peacock, Jacqueline D ^a   Cherba, David ^a   Kampfschulte, Kevin ^a   Smith, Mallory K ^a,b   Monks, Noel R ^a   Webb, Craig P ^a   Steensma, Matthew ^a,c,d  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b HOPE COLLEGE   (United States)

^c SPECTRUM HEALTH   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1;

ABCC1 GENE; ARTICLE; COMPUTER PREDICTION; COMPUTER PROGRAM; CONTROLLED STUDY; DNA REPAIR; DRUG TRANSPORT; GENE EXPRESSION; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MICROARRAY ANALYSIS; MOLECULARLY TARGETED THERAPY; PERSONALIZED MEDICINE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA DAMAGE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NERVE SHEATH NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE;

EID: 84883891024     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-213     Document Type: Article

References (56)

1. Evans DGR, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002, 39:311-314. 10.1136/jmg.39.5.311, 1735122, 12011145.
2. Ducatman BS SB, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. a clinicopathologic study of 120 cases. Cancer 1986, 57:2006-2021. 10.1002/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6, 3082508.
3. Ingham S, Huson SM, Moran A, Wylie J, Leahy M, Evans DGR. Malignant peripheral nerve sheath tumours in NF1: improved survival in women and in recent years. Eur J Cancer 2011, 47:2723-2728. 10.1016/j.ejca.2011.05.031, 21700447.
4. Slomiany MG, Dai L, Bomar PA, Knackstedt TJ, Kranc DA, Tolliver L, Maria BL, Toole BP. Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides. Cancer Res 2009, 69:4992-4998. 10.1158/0008-5472.CAN-09-0143, 3655760, 19470767.
5. Ho-Jin P, Su-Jin L, Young Bae S, Hyun-Seok J, JaeHo H, Young-Bae K, Hyunee Y, Jeong S-Y. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Int J Oncol 2012, 42:657-666.
6. Suto RAY, Lee YH, Ueyama Y, Yamazaki H, Kijima H, Hiraoka N, Fukuda H, Tamaoki N, Nakamura M. A case of malignant schwannoma with overexpression of multidrug resistance gene (MDR1) after chemotherapy. Anticancer Res 1997, 17:2273-2277.
7. Komdeur R, Plaat BEC, van der Graaf WTA, Hoekstra HJ, Hollema H, van den Berg E, Zwart N, Scheper RJ, Molenaar WM. Expression of multidrug resistance proteins, P-gp, MRP1 and LRP, in soft tissue sarcomas analysed according to their histological type and grade. Eur J Cancer 2003, 39:909-916. 10.1016/S0959-8049(03)00029-7, 12706359.
8. Oda Y, Saito T, Tateishi N, Ohishi Y, Tamiya S, Yamamoto H, Yokoyama R, Uchiumi T, Iwamoto Y, Kuwano M, Tsuneyoshi M. ATP-binding cassette superfamily transporter gene expression in human soft tissue sarcomas. Int J Cancer 2005, 114:854-862. 10.1002/ijc.20589, 15609299.
9. Miller SJ, Rangwala F, Williams J, Ackerman P, Kong S, Jegga AG, Kaiser S, Aronow BJ, Frahm S, Kluwe L, et al. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res 2006, 66:2584-2591. 10.1158/0008-5472.CAN-05-3330, 16510576.
10. Su-Jin Lee H-JP, Young-Hwa K, Bo-Young K, Hyun-Seok J, Kim HJ, Jae-Ho H, Hyunee Y, Seon-Yong J. Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells. Int J Mol Med 2012, 30:443-450.
11. Lopez G, Torres K, Liu J, Hernandez B, Young E, Belousov R, Bolshakov S, Lazar AJ, Slopis JM, McCutcheon IE, et al. autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Cancer Res 2011, 71:185-196. 10.1158/0008-5472.CAN-10-2799, 3064267, 21084276.
12. Lonning PE, Knappskog S. Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers. Oncogene 2013, Advance online publication 11 March 2013; doi: 10.1038/onc.2013.48.
13. Tsioli PGPE, Giaginis C, Theocharis SE. DNA repair systems in Rhabdomyosarcoma. Histol Histopathol 2013, 8:971-984.
14. Maria Papaefthymiou CG, Stamatios T. DNA repair alterations in common pediatric malignancies. Med Sci Monit 2008, 14:8-15.
15. Skotheim RI, Kallioniemi A, Bjerkhagen B, Mertens F, Brekke HR, Monni O, Mousses S, Mandahl N, Sœter G, Nesland JM, et al. Topoisomerase-IIα is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. J Clin Oncol 2003, 21:4586-4591. 10.1200/JCO.2003.07.067, 14673046.
16. Levy P, Vidaud D, Leroy K, Laurendeau I, Wechsler J, Bolasco G, Parfait B, Wolkenstein P, Vidaud M, Bieche I. Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR. Mol Cancer 2004, 3:20. 10.1186/1476-4598-3-20, 493279, 15255999.
17. Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol 1994, 45:649-656.
18. Tierney JF, Stewart LA, Parmar MKB. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997, 350:1647-1654.
19. Kroep JR, Ouali M, Gelderblom H, Le Cesne A, Dekker TJA, Van Glabbeke M, Hogendoorn PCW, Hohenberger P. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. Ann Oncol 2011, 22:207-214. 10.1093/annonc/mdq338, 3003614, 20656792.
20. D'Adamo DR. Appraising the current role of chemotherapy for the treatment of sarcoma. Semin Oncol 2011, 38(Supplement 3):S19-S29.
21. Upadhyaya M, Spurlock G, Majounie E, Griffiths S, Forrester N, Baser M, Huson SM, Gareth Evans D, Ferner R. The heterogeneous nature of germline mutations in NF1 patients with malignant peripheral serve sheath tumours (MPNSTs). Hum Mutat 2006, 27:716.
22. Mantripragada KK, Spurlock G, Kluwe L, Chuzhanova N, Ferner RE, Frayling IM, Dumanski JP, Guha A, Mautner V, Upadhyaya M. High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. Clin Cancer Res 2008, 14:1015-1024. 10.1158/1078-0432.CCR-07-1305, 18281533.
23. Fishbein L, Zhang X, Fisher LB, Li H, Campbell-Thompson M, Yachnis A, Rubenstein A, Muir D, Wallace MR. In vitro studies of steroid hormones in neurofibromatosis 1 tumors and schwann cells. Mol Carcinog 2007, 46:512-523. 10.1002/mc.20236, 17393410.
24. Kobayashi C, Oda Y, Takahira T, Izumi T, Kawaguchi K, Yamamoto H, Tamiya S, Yamada T, Iwamoto Y, Tsuneyoshi M. Aberrant expression of CHFR in malignant peripheral nerve sheath tumors. Mod Pathol 2006, 19:524-532. 10.1038/modpathol.3800548, 16554732.
25. Mo W, Chen J, Patel A, Zhang L, Chau V, Li Y, Cho W, Lim K, Xu J, Lazar Alexander J, et al. CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell 2013, 152:1077-1090. 10.1016/j.cell.2013.01.053, 23434321.
26. Torres KE, Zhu Q-S, Bill K, Lopez G, Ghadimi MP, Xie X, Young ED, Liu J, Nguyen T, Bolshakov S, et al. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res 2011, 17:3943-3955. 10.1158/1078-0432.CCR-11-0193, 3117912, 21540237.
27. Watanabe T, Oda Y, Tamiya S, Masuda K, Tsuneyoshi M. Malignant peripheral nerve sheath tumour arising within neurofibroma. an immunohistochemical analysis in the comparison between benign and malignant components. J Clin Pathol 2001, 54:631-636. 10.1136/jcp.54.8.631, 1731495, 11477120.
28. Ottini L, Esposito DL, Richetta A, Carlesimo M, Palmirotta R, Verì MC, Battista P, Frati L, Caramia FG, Calvieri S, et al. Alterations of microsatellites in Neurofibromas of von Recklinghausen's disease. Cancer Res 1995, 55:5677-5680.
29. Feitsma H, Kuiper RV, Korving J, Nijman IJ, Cuppen E. Zebrafish with mutations in mismatch repair genes develop neurofibromas and other tumors. Cancer Res 2008, 68:5059-5066. 10.1158/0008-5472.CAN-08-0019, 18593904.
30. Kobayashi C, Oda Y, Takahira T, Izumi T, Kawaguchi K, Yamamoto H, Tamiya S, Yamada T, Oda S, Tanaka K, et al. Chromosomal aberrations and microsatellite instability of malignant peripheral nerve sheath tumors: a study of 10 tumors from nine patients. Cancer Genet Cytogenet 2006, 165:98-105. 10.1016/j.cancergencyto.2005.07.006, 16527603.
31. Croes D, Couche F, Wodak S, van Helden J. Inferring meaningful pathways in weighted metabolic networks. J Mol Biol 2006, 356:222-236. 10.1016/j.jmb.2005.09.079, 16337962.
32. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, et al. DrugBank 3.0: a comprehensive resource for 'Omics' research on drugs. Nucleic Acids Res 2011, 39:D1035-D1041. 10.1093/nar/gkq1126, 3013709, 21059682.
33. Nikolsky Y, Ekins S, Nikolskaya T, Bugrim A. A novel method for generation of signature networks as biomarkers from complex high throughput data. Toxicol Lett 2005, 158:20-29. 10.1016/j.toxlet.2005.02.004, 15871913.
34. Dezso Z, Nikolsky Y, Nikolskaya T, Miller J, Cherba D, Webb C, Bugrim A. Identifying disease-specific genes based on their topological significance in protein networks. BMC Syst Biol 2009, 3:36. 10.1186/1752-0509-3-36, 2678983, 19309513.
35. Saulnier Sholler WF GL, Bergendahl G, Currier E, Lenox SR, Bond J, Slavik M, Roberts W, Mitchell D, Eslin D, Kraveka J, Kaplan J, Parikh N, Malempati S, Hanna G, Eugster E, Cherba D, Miller J, Webb C. A pilot trial testing the feasibility of using molecular-guided therapy in patients with recurrent neuroblastoma. J Cancer Ther 2012, 3:602-612.
36. Miller SJ, Jessen WJ, Mehta T, Hardiman A, Sites E, Kaiser S, Jegga AG, Li H, Upadhyaya M, Giovannini M, et al. Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med 2009, 1:236-248. 10.1002/emmm.200900027, 3378132, 20049725.
37. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there?. Nat Rev Drug Discov 2006, 5:993-996. 10.1038/nrd2199, 17139284.
38. Furge KA, Chen J, Koeman J, Swiatek P, Dykema K, Lucin K, Kahnoski R, Yang XJ, Teh BT. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res 2007, 67:3171-3176. 10.1158/0008-5472.CAN-06-4571, 17409424.
39. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Sci 2006, 313:1929-1935.
40. Von Hoff DD, Stephenson JJ, Rosen P, Loesch DM, Borad MJ, Anthony S, Jameson G, Brown S, Cantafio N, Richards DA, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010, 28:4877-4883. 10.1200/JCO.2009.26.5983, 20921468.
41. Muir D, Neubauer D, Lim IT, Yachnis AT, Wallace MR. Tumorigenic properties of neurofibromin-deficient neurofibroma Schwann cells. Am J Pathol 2001, 158:501-513. 10.1016/S0002-9440(10)63992-2, 1850316, 11159187.
42. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990, 82:1107-1112. 10.1093/jnci/82.13.1107, 2359136.
43. Volm M, Mattern J. Elevated expression of thymidylate synthase in doxorubicin resistant human non small cell lung carcinomas. Anticancer Res 1992, 12:2293-2296.
44. Chekhun VF, Kulik GI, Yurchenko OV, Tryndyak VP, Todor IN, Luniv LS, Tregubova NA, Pryzimirska TV, Montgomery B, Rusetskaya NV, Pogribny IP. Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells. Cancer Lett 2006, 231:87-93. 10.1016/j.canlet.2005.01.038, 16356834.
45. Fieber LA, González DM, Wallace MR, Muir D. Delayed rectifier K currents in NF1 Schwann cells: pharmacological block inhibits proliferation. Neurobiol Dis 2003, 13:136-146. 10.1016/S0969-9961(03)00031-7, 12828937.
46. Choi Y, Yu A. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des in press.
47. Binkhathlan Z, Lavasanifar A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr Cancer Drug Targets 2013, 13:326-346. 10.2174/15680096113139990076, 23369096.
48. Falasca M, Linton KJ. Investigational ABC transporter inhibitors. Expert Opin Investig Drugs 2012, 21:657-666. 10.1517/13543784.2012.679339, 22493979.
49. Cole SPC, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, Deeley RG. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994, 54:5902-5910.
50. Slovak ML, Hoeltge GA, Dalton WS, Trent JM. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Res 1988, 48:2793-2797.
51. Long BH, Wang L, Lorico A, Wang RCC, Brattain MG, Casazza AM. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res 1991, 51:5275-5283.
52. Brems H, Beert E, de Ravel T, Legius E. Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol 2009, 10:508-515. 10.1016/S1470-2045(09)70033-6, 19410195.
53. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A 2005, 102:8573-8578. 10.1073/pnas.0503224102, 1142482, 15937108.
54. Zeldis JB, Schafer PH, Bennett BL, Mercurio F, Stirling DI. Potential new therapeutics for Waldenstrom's macroglobulinemia. Semin Oncol 2003, 30:275-281. 10.1053/sonc.2003.50078, 12720152.
55. Melchert M, List A. The thalidomide saga. Int J Biochem Cell Biol 2007, 39:1489-1499. 10.1016/j.biocel.2007.01.022, 17369076.
56. Payvandi F, Wu L, Haley M, Schafer PH, Zhang L-H, Chen RS, Muller GW, Stirling DI. Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-α, IL-1β, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol 2004, 230:81-88. 10.1016/j.cellimm.2004.09.003, 15598423.